Search

Your search keyword '"Rossi, Davide"' showing total 3,090 results

Search Constraints

Start Over You searched for: Author "Rossi, Davide" Remove constraint Author: "Rossi, Davide"
3,090 results on '"Rossi, Davide"'

Search Results

51. A transprecision floating-point cluster for efficient near-sensor data analytics

52. DORY: Automatic End-to-End Deployment of Real-World DNNs on Low-Cost IoT MCUs

53. Performance-Aware Predictive-Model-Based On-Chip Body-Bias Regulation Strategy for an ULP Multi-Core Cluster in 28nm UTBB FD-SOI

54. Always-On 674uW @ 4GOP/s Error Resilient Binary Neural Networks with Aggressive SRAM Voltage Scaling on a 22nm IoT End-Node

55. Enabling Mixed-Precision Quantized Neural Networks in Extreme-Edge Devices

56. A 0.5GHz 0.35mW LDO-Powered Constant-Slope Phase Interpolator with 0.22$\%$ INL

57. Arnold: an eFPGA-Augmented RISC-V SoC for Flexible and Low-Power IoT End-Nodes

58. Energy-Efficient Hardware-Accelerated Synchronization for Shared-L1-Memory Multiprocessor Clusters

61. PULP-NN: Accelerating Quantized Neural Networks on Parallel Ultra-Low-Power RISC-V Processors

62. On Formal Choreographic Modelling: A Case Study in EU Business Processes

63. ControlPULP: A RISC-V Power Controller for HPC Processors with Parallel Control-Law Computation Acceleration

64. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

65. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy

66. PULP-HD: Accelerating Brain-Inspired High-Dimensional Computing on a Parallel Ultra-Low Power Platform

67. Hyperdrive: A Multi-Chip Systolically Scalable Binary-Weight CNN Inference Engine

68. NEURAghe: Exploiting CPU-FPGA Synergies for Efficient and Flexible CNN Inference Acceleration on Zynq SoCs

69. A Transprecision Floating-Point Platform for Ultra-Low Power Computing

70. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

71. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

72. Streamlining the OpenMP Programming Model on Ultra-Low-Power Multi-core MCUs

73. Genetic and phenotypic attributes of splenic marginal zone lymphoma

74. A sub-mW IoT-endnode for always-on visual monitoring and smart triggering

75. Neurostream: Scalable and Energy Efficient Deep Learning with Smart Memory Cubes

78. An IoT Endpoint System-on-Chip for Secure and Energy-Efficient Near-Sensor Analytics

79. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

80. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

82. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

83. Table S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

84. Figure S5 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

85. Supplementary Table 7 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

86. Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

87. Supplementary Table 5 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

88. Data from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

89. Supplementary Table 6 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

90. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

91. Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

92. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma

94. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

95. A Heterogeneous RISC-V Based SoC for Secure Nano-UAV Navigation

97. A multidisciplinary approach for the physic-chemical characterization of peloids to new perspectives in the development for 'hydrothermal Developing Countries' using partecipatory methodology

Catalog

Books, media, physical & digital resources